Cidara Therapeutics inked a deal worth up to $780 million with Johnson & Johnson to develop and commercialize Cidara’s candidate CD388 for the prevention and treatment of seasonal and pandemic influenza.
As the world tries to limit the spread of the novel coronavirus that causes COVID-19, there is some hope that warmer weather will cause the virus to dwindle, like what happens with seasonal influenza. Though research indicates that COVID-19 could be seasonal, returning in the fall.
Seqirus snagged U.S. FDA approval for Fluad Quadrivalent, the first quadrivalent adjuvanted influenza vaccine developed to help protect adults 65 years and older against seasonal influenza.
